eligibility_summary
Adults ≥18 with platinum‑resistant (<6 mo) recurrent/persistent non‑mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer, measurable disease, archival FFPE for TROP‑2, ECOG 0–1, adequate marrow/renal/hepatic, ≤2 prior lines, washouts/recovery, neg pregnancy test/contraception. Exclude pregnancy, recent other malignancy, cardiac/respiratory/unstable illness, active HIV/HBV/HCV viremia, CNS mets, bulky >7 cm, bleeding/GI risks, Gilbert’s, UGT1A1 inhibitors, prior irinotecan/topo‑I.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm phase 2 trial of sacituzumab govitecan (IMMU-132), an antibody–drug conjugate. Drug: humanized anti–Trop-2 IgG mAb linked to SN-38 (active metabolite of irinotecan), a small-molecule topoisomerase I inhibitor. Mechanism: antibody binds Trop-2 on tumor cells, is internalized, then releases SN-38 to inhibit topoisomerase I, causing DNA replication stress and breaks, leading to cell-cycle arrest and apoptosis, hydrolyzable linker may enable bystander killing. Targets: Trop-2–expressing epithelial ovarian/fallopian tube/primary peritoneal cancer cells, pathways include Trop-2–mediated uptake, topoisomerase I/DNA replication, and DNA damage response. UGT1A1 metabolism is clinically relevant.